Public Release:  JCI early table of contents for Jan. 16, 2014

Journal of Clinical Investigation

Macrophages target tumor cells following monoclonal antibody therapy

Monoclonal antibodies directed against tumor antigens have proven effective for treating some forms of cancer. Despite the increasing use of monoclonal antibody therapy, it is not clear how these antibodies drive tumor removal. In this issue of the Journal of Clinical Investigation, Marjolein van Egmond and colleagues at the VU University Medical Center found that macrophage populations mediate tumor cell removal following monoclonal antibody treatment by actively phagocytosing tumor cells. Macrophage-dependent tumor cell removal required both the high affinity and low affinity Fc receptors. This study suggests that monoclonal antibody therapies that are optimized to enhance macrophage recruitment and activity may enhance removal of circulating tumor cells in cancer patients.

TITLE: Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

AUTHOR CONTACT: Marjolein van Egmond
VU University Medical Center, Amsterdam, , NLD
Phone: +3120 4445975; Fax: ; E-mail:

View this article at:

Targeting a cell cycle inhibitor promotes β cell replication

One of the factors underlying the development of type 2 diabetes is loss of β cell mass, resulting in decreased insulin production. Once lost, β cell mass cannot be restored. In contrast, infants with focal hyperinsulinism of infancy exhibit rapid expansion of the β cell mass due to a silencing of a region of chromosome 11 that includes the gene encoding the cell cycle inhibitor p57Kip2. In this issue of the Journal of Clinical Investigation, Klaus Kaestner and colleagues at the University of Pennsylvania demonstrate that silencing the gene encoding p57Kip2 in isolated adult human islets promotes β cell replication and that these new cells exhibit many properties associated with β cells. This study provides an explanation for excessive β cell expansion in children with focal hyperinsulinism and suggests that targeting the p57Kip2 pathway in adults with type 2 diabetes may improve β cell function.

TITLE: Targeting the cell cycle inhibitor p57Kip2 promotes adult human β cell replication

AUTHOR CONTACT: Klaus Kaestner
University of Pennsylvania, Perelman School of Medicine, Philadeplhia, PA, USA
Phone: 215.898.8759; Fax: 215.573.5892; E-mail:

View this article at:


TITLE: Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy

Biomedicum Helsinki; University of Helsinki, Helsinki, , FIN
Phone: +358 9 191 25511; Fax: +358 9 191 25510; E-mail:

View this article at:

TITLE: Nutrient sensing by the mitochondrial transcription machinery dictates oxidative phosphorylation

UMass Medical School, Worcester, MA, USA
Phone: 5088566907; E-mail:

View this article at:

TITLE: Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis

University of Michigan, Ann Arbor,, MI, USA
Phone: 734-615-1989; Fax: 734-763-1581;

View this article at:

TITLE: Changes in neural network homeostasis trigger neuropsychiatric symptoms

Max Delbrück Center for Molecular Medicine, Berlin, , DEU
Phone: +49-30-94063062; E-mail:

View this article at:

TITLE: Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation

INSERM U1009, Villejuif, , FRA
Phone: 00 33 1 42 11 46 71; Fax: 00 33 1 42 11 52 40; E-mail:

View this article at:

TITLE: Prion disease tempo determined by host-dependent substrate reduction

University of Alberta, Edmonton, AB, CAN
Phone: 780-492-9377; E-mail:

View this article at:


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.